Connect with us


TMRW Life Sciences enters the UK fertility market

TMRW’s automated platform is hoped to help fertility clinics reduce the risk of specimen mix-up, error and loss



The US fertility technology company TMRW Life Sciences has announced the adoption of its platform in the UK.

The platform, also known as CryoRobot Select (CRS), aims to modernise the management and storage of frozen eggs and embryos by combining hardware and software to track, monitor and store frozen eggs and embryos.

The Hewitt Fertility Centre in Liverpool, England, will become the first clinic outside of the US to adopt TMRW’s CRS.

Thanks to advances in assisted reproductive technology, more people than ever before are building families and storing frozen eggs and embryos. Despite this, many fertility providers still rely on manual storage systems and hand-labelled identification methods.

Over the last three years, The Hewitt Fertility Centre has completed studies to quantify the potential hazards associated with manual cryostorage of eggs and embryos following fertility treatment.

The studies demonstrated that even when clinics use witnessing systems that use radio frequency identification (RFID) and establish handling procedures, manual cryostorage for IVF is still prone to far too many potential points of failure.

Through TMRW’s CRS platform, frozen specimens will now be digitally identified and tracked with RFID technology, managed with automated robotics and remotely monitored around the clock for the first time in the UK.

The innovation is hoped to reduce potential points of failure by 94 per cent compared to manual specimen management and storage systems and help clinics reduce the risk of specimen mix-up, error and loss.

“I am delighted for Hewitt Fertility patients and for the scientific team that we can finally announce the introduction of TMRW’s CRS into our clinical pathways” said Dr Rachel Gregoire, scientific director/HFEA person responsible for The Hewitt Fertility Centres.

“It is a credit to Rebecca, lead clinical embryologist and the team who have worked tirelessly with the incredible people at TMRW to make this happen.

“Almost three years ago, Hewitt demonstrated that manual cryostorage involves potential unnecessary handling events of patient samples in storage and Hewitt is so pleased to be the first fertility clinic outside of the US to offer TMRW’s CE-marked technology for our patients.”

She added: “We thank Liverpool Women’s NHS Foundation Trust for listening to us and for investing in this technology so that the Hewitt Fertility Centres can continue to be leaders in offering safe and innovative fertility treatments.”

Louis Villalba, chief executive officer at TMRW, said: “Our partnership with The Hewitt Fertility Centre represents the first step in our global expansion and illustrates our commitment to raising the global standard of care.

“We applaud The Hewitt Fertility Centre for being the first IVF clinic outside of the United States to adopt our CE-marked and FDA cleared specimen management system.

“Our collaboration heralds a new era of safety and precision in managing frozen eggs and embryos in the UK.”

TMRW received a CE mark for its CRS platform in September, enabling commercialisation across the UK and Europe. The company said the European approval, along with an earlier clearance by the US FDA, made its robotic systems a new global standard.

To receive the Femtech World newsletter, sign up here.


‘Groundbreaking’ endometriosis study identifies patient priorities



A “groundbreaking” study into endometriosis has identified three areas for future research that can help improve the outcomes for women with the condition.

The study, commissioned by Endometriosis New Zealand, attracted 1,262 participants, including 1,024 people with confirmed endometriosis, making it the largest ever study involving endometriosis patients and supporters in New Zealand.

Study participants identified the management and treatment of endometriosis, the need for a better understanding of its cause and improvements to diagnostic capability as the three main priorities for further research.

While these findings provide a clear pathway for future work, Endometriosis New Zealand chief executive, Tanya Cooke, said endometriosis research had historically been underfunded.

“With an estimated 120,000 New Zealanders living with endometriosis, much more needs to be invested into finding solutions,” Cooke explained.

“The reality is the outcomes for many endometriosis patients are pretty poor, with diagnosis often taking many years and treatment patchy across the country.”

Estimates based on Australian data suggest that endometriosis is likely to be costing New Zealand somewhere in the range of $1.3-1.5bn annually through increased healthcare costs and lost workforce productivity.

Cooke said: “The good news is that our findings align closely with those in Australia and provide three clear priorities for future research – improved treatment options, causation and better diagnostic capability.

“What New Zealand now requires is proper funding for a future research programme that can investigate these priorities more closely and improve the outcomes for individuals living with endometriosis.”

To receive the Femtech World newsletter, sign up here.

Continue Reading


Virtual care platform secures US$46m to address US maternal health crisis

Pomelo Care will use the funding to scale its care model and improve maternal and infant outcomes



Marta Bralic Kerns, founder and CEO of Pomelo Care

The US virtual maternity care platform Pomelo Care has secured US$46m in funding to address the US maternal health crisis.

One in 10 babies born in the US today start their life in a neonatal intensive care unit.

Healthcare access continues to worsen, with one in eight births occurring in US counties with limited-to-no access to maternal care. Due to significant gaps in postpartum care, about half of pregnancy-related deaths in the US occur after hospital discharge.

The evidence exists for how to identify people at highest risk for complications and which interventions are most effective, but existing data gaps and provider capacity challenges make it difficult to apply these interventions at scale.

Pomelo has developed a care model that aims to address these challenges by analysing claims and health record data to identify individual risk factors and providing virtual pregnancy, postpartum, and infant care to patients to reduce those risks.

“We’ve long known what works to reduce maternal and infant complications,” said Marta Bralic Kerns, founder and CEO of Pomelo Care.

“The questions have always been: can you identify the patients who are at highest risk, can you deeply engage them in care to drive uptake of the prevention strategies we know work, and can you do it in the highest risk populations with the most limited access to care?”

“This data demonstrates that we absolutely can. And with this additional funding, we’ll have the opportunity to scale our care model to more pregnant people across the country.”

The funding, led by existing investors First Round Capital and Andreessen Horowitz (a16z) Bio + Health, is hoped to help Pomelo accelerate its partnerships with payors across the US and increase access to “evidence-based” care.

Josh Kopelman, partner at First Round Capital and Pomelo board member, said: “It’s rare to come across an opportunity where the incentives between patient, provider and payor are all aligned.

“Marta and the Pomelo team have found an incredible opportunity to dramatically improve outcomes for the highest risk populations, while helping payors reduce their avoidable costs.”

Vineeta Agarwala, general partner at a16z Bio + Health and Pomelo board member, added: “Pomelo is one among a small set of health tech companies that have earned true scale.

“This scale is evident in our partnerships with major Medicaid and commercial plans covering over three million lives, which create the opportunity to collaborate with OB providers, labour and delivery wards, and NICUs nationwide, while serving hundreds of thousands of expecting mothers and newborns with high quality, technology-enabled care.”

To receive the Femtech World newsletter, sign up here.

Continue Reading


One in three UK fertility patients seek treatment abroad due to high costs

Expensive fertility treatments prompt UK patients to seek help abroad



One in three fertility patients in the UK seek treatment abroad due to high costs, a new survey has shown.

Fertility Family has gathered insights from 429 UK participants who have experienced difficulties with infertility.

The Infertility Awareness Report found that the high cost of fertility treatment in the UK has driven over one in four people to spend over £10,000 on both treatments and investigative procedures.

The research showed around 35 per cent of people struggling with infertility have considered seeking fertility treatment abroad due to the prospect of lower costs.

Of those seeking fertility treatment in a foreign country, however, only 14 per cent believed that clinics abroad have a higher success rate.

Of those actively trying to conceive almost one in five have used their life savings in the pursuit of having a child, whilst 25 per cent have paid for their fertility treatments using a credit card.

Dr Gill Lockwood, consultant at Fertility Family, said: “While we tend to cast our gaze on women when it comes to infertility, case studies have shown that infertility can impact both women and men in similar ways. However, women have been observed to seek help more than men.

“Although the psychological struggles of infertility can be overwhelming, many patients ultimately reach some type of resolution. Some of the alternatives include becoming parents to a relative’s children, adopting children, or deciding to adopt a child-free lifestyle.

“Needless to say, this resolution is usually psychologically demanding, and patients may feel forever impacted by the experience of infertility.”

A combination of fertility struggles and accessible healthcare have impacted people across the UK significantly, with one in two admitting to feeling “ashamed” due to their difficulties trying to conceive.

A further 31 per cent reported feeling that other people think “less” of them due to their fertility struggles, showcasing the need for better mental health support.

To receive the Femtech World newsletter, sign up here.

Continue Reading


Copyright © 2023 Aspect Publishing Ltd. All Rights Reserved.